Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cadence Design Systems Inc (CDNS) vs TransMedics Group Inc (TMDX) Price & Performance

Cadence Design Systems IncTrade
TransMedics Group IncTrade

Price performance (Past 24H)

Key statistics

Cadence Design Systems Inc vs TransMedics Group Inc — how do they compare? Cadence Design Systems Inc trades at $324.92 (market cap $90.20B), while TransMedics Group Inc trades at $86.28 (market cap $3.10B). The key difference: Cadence Design Systems Inc is far larger — about 29.1× TransMedics Group Inc's market cap, and Cadence Design Systems Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.

CDNSTMDX
Market Cap
$90.20B$3.10B
Sector
TechnologyTechnology
52-Week High
$416.39$150.42
52-Week Low
$265.66$61.99
Enterprise Value
$91.41B$3.49B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cadence Design Systems Inc

Cadence Design Systems (CDNS) trades at $331.91, down 2.16% amid a bearish technical signal, though it remains supported by strong fundamentals. The company reported Q2 2026 earnings that beat estimates, with revenue growth of 24.2% driven by AI demand, and raised its full-year outlook. Analyst consensus is strongly bullish with an average price target of $415.11, representing 25% upside potential from current levels.

The stock offers compelling growth prospects from AI-driven semiconductor design demand, with record backlog of $8.1 billion supporting future revenue visibility. Key risks include high valuation multiples (P/E 65.12) and potential semiconductor cycle volatility. Institutional ownership remains strong with recent position increases by major funds like Amundi.

TransMedics Group Inc

TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.

Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.

Returns comparison

Trailing returns across standard periods

About Cadence Design Systems Inc

Cadence Design Systems is a provider of electronic design automation software, intellectual property, and system design and analysis products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. Cadence offers a portfolio of design IP, as well as system design and analysis products, which enable system-level analysis and verification solutions. Cadence's comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers, alongside secular digitalization of various end markets, benefits EDA vendors like Cadence.

Read more on CDNS

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX